Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O43511

UPID:
S26A4_HUMAN

ALTERNATIVE NAMES:
Sodium-independent chloride/iodide transporter; Solute carrier family 26 member 4

ALTERNATIVE UPACC:
O43511; B7Z266; O43170

BACKGROUND:
The protein Pendrin, encoded by SLC26A4, serves as a versatile transporter for chloride and iodide, facilitating various electroneutral exchanges critical for cellular function. Its ability to transport these ions without the involvement of sodium ions highlights its unique mechanism of action. Known alternatively as Sodium-independent chloride/iodide transporter and Solute carrier family 26 member 4, Pendrin's multifaceted role in ion transport underscores its biological significance.

THERAPEUTIC SIGNIFICANCE:
Involvement of Pendrin in diseases such as Pendred syndrome and autosomal recessive deafness underscores its clinical relevance. These conditions, linked to genetic variants affecting Pendrin, highlight the protein's potential as a target for therapeutic intervention. Exploring Pendrin's function further could unveil novel approaches to treating related auditory and thyroid disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.